Background: Various oral hypoglycemic agents have already been administered to type-2 diabetic patients to normalize their plasma glucose concentrations but they have not had complete and sustained success. In recent years, bromocriptine has been tried with controversial results. In present study, the effect of bromocriptine on glycemic control was evaluated in obese type-2 diabetic patients. Methods: In a double-blind placebo-controlled clinical trial, 40 obese patients with type-2 diabetes (aged 32–70 years) were randomly allocated to the two treatment groups. The first group received bromocriptine (2.5 mg daily) for a total of 3 months. The second group received placebo. They had been uncontrolled on fixed doses of glibenclamide or its combination with metformin in the 3 months before enrolling in the study. The fasting plasma glucose (FPG) level and glycosylated hemoglobin (HbA1) were measured and body mass index (BMI) was calculated before and 1, 2 and 3 months after treatment. Results: The FPG level decreased in the bromocriptine-treated group from 10.59 ± 0.42 to 9.06 ± 0.41 mmol/l (mean ± SEM; p < 0.01), whereas in the placebo group it was not changed, 10.69 ± 0.52 and 10.6 ± 0.57 mmol/l, respectively. The HbA1 concentration was reduced in the bromocriptine-treated group from 9.9 ± 0.3 to 9.5 ±0.2% (p = 0.06), whereas it increased in the placebo-treated group from 10.2 ± 0.3 to 11.3 ± 0.6% (p < 0.05). The differences in HbA1 (1.8%, p < 0.01) and FPG (1.55 mmol/l, p < 0.05) levels between the bromocriptine and placebo groups at 3 months were significant. No changes in body weight or BMI occurred during the study in either placebo- or bromocriptine-treated group. Conclusion: The data further support the contention that bromocriptine improves glycemic control in obese type-2 diabetic patients, although the mechanism of action remains to be determined.

1.
Maggio CA, Pi-Sunyer FX: The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997;20:1744–1766.
2.
Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S: The metabolically obese, normal-weight individual revisited. Diabetes 1998;47:699–713.
3.
Cowie CC, Harris MI, Eberhardt MS: Frequency and determinants of screening for diabetes in the US. Diabetes Care 1994;17:1158–1163.
4.
Cincotta AH, Meier AH: Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism 1995;44:1349–1355.
5.
Cincotta AH, Tozzo E, Scislowski PW: Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci 1997;61:951–956.
6.
Liang Y, Jetton TL, Lubkin M, Meier AH, Cincotta AH: Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse. Cell Mol Life Sci 1998;54:703–711.
7.
Erminio C, Greengard P: Ergot compounds and brain function: Neuroendocrine and neuropsychiatric aspects. Adv Biochem Psychopharmacol 1980;23:41–62.
8.
Southern L, Cincotta A, Meier A, Binder T, Watkins K: Bromocriptine-induced reduction of body fat in pigs. J Anim Sci 1990;68:931–936.
9.
Cincotta AH, Schiller BC, Meier AH: Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism 1991;40:639–644.
10.
Cincotta AH, Meier AH, Southern LL: Bromocriptine alters hormone rhythms and lipid metabolism in swine. Ann Nutr Metab 1989;33:305–314.
11.
Cincotta AH, MacEachern TA, Meier AH: Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol 1993;264:E285–E293.
12.
Luo S, Liang Y, Cincotta AH: Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology 1999;69:160–166.
13.
Cincotta AH, Meier AH: Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996;19:667–670.
14.
Scobie IN, Kesson CM, Ratcliffe JG, Maccuish AC: The effects of prolonged bromocriptine administration on PRL secretion GH and glycaemic control in stable insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf) 1983;18:179–185.
15.
Meier AH, Cincotta AH, Lovell WC: Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 1992;48:248–253.
16.
Pijl H, Ohashi S, Matsuda M, et al: Bromocriptine: A novel approach to the treatment of type 2 diabetes. Diabetes Care 2000;23:1154–1161.
17.
Wasada T, Kawahara R, Iwamoto Y: Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care 2000;23:1039–1040.
18.
Gardner MJ, Altman DG: Statistics with Confidence. London, British Medical Association, 1989.
19.
Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN: Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994;17:30–36.
20.
Wing RR, Blair E, Marcus M, Epstein LH, Harvey J: Year-long weight loss treatment for obese patients with type II diabetes: Does including an intermittent very-low-calorie diet improve outcome? Am J Med 1994;97:354–362.
21.
Cincotta AH, Meier AH, Cincotta JM: Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: A new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999;8:1683–1707.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.